Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199846 · ClinicalTrials.gov registry record
Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 650
- Enrollment target
NCT03199846: Completed study, sponsored by Bristol-Myers Squibb.
NCT03199846 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 650 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03199846 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 650 participants
- Enrollment target
Study Summary
This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an oversample (Part 2).
Primary Outcome
Distribution of treatment patterns for advanced melanoma patients including, treatment regimen selection and rationale, as well as time to initiation of therapy and type of therapy
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2017-12-31 |
What the finished NCT03199846 record still lists
NCT03199846 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT03199846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03199846 about?
NCT03199846 is a clinical study titled "Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States". This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an oversample (Part 2).
What is the current status of trial NCT03199846?
This trial is currently completed. The enrollment target is 650 participants. The study started on 2016-10-25. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT03199846?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT03199846?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI